GIP/GLP-1/glucagon agonist
Retatrutide clinical trials
Answer
Retatrutide has 41 registered trials: 11 running, 21 completed, 0 stopped early. 2 posted results.
Trial registerClinicalTrials.gov and EU CTIS, read 2026-10-03
| Trial | Title | Status | Phase | Registered | Results |
|---|---|---|---|---|---|
| 2023-503658-11-00 Trial register | J1I-MC-GZBK: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus Who Have Obesity or | Not stated | 3 | - | - |
| NCT06260722 Trial register | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 | running, but no longer enrolling | 3 | 2024-02-15 | - |
| NCT07035093 Trial register | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | running, but no longer enrolling | 3 | 2025-06-24 | - |
| NCT06383390 Trial register | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | running, but no longer enrolling | 3 | 2024-04-25 | - |
| NCT07165028 Trial register | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | currently recruiting participants | 3 | 2025-09-10 | - |
| 2025-522674-36-00 Trial register | N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-A | Not stated | 3 | - | - |
| NCT05929066 Trial register | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | completed | 3 | 2023-07-03 | - |
| 2024-511450-49-00 Trial register | J1I-MC-GZBP: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity | Not stated | 3 | - | - |
| NCT07629401 Trial register | Pre-approval Expanded Access of Retatrutide (LY3437943) | available | - | 2026-06-05 | - |
| NCT05882045 Trial register | A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | completed | 3 | 2023-05-31 | - |
| NCT05929079 Trial register | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | completed | 3 | 2023-07-03 | - |
| NCT06297603 Trial register | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Ba | running, but no longer enrolling | 3 | 2024-03-07 | - |
| NCT06662383 Trial register | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | running, but no longer enrolling | 3 | 2024-10-28 | - |
| NCT06982859 Trial register | A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | running, but no longer enrolling | 1 | 2025-05-21 | - |
| 2023-503659-88-00 Trial register | J1I-MC-GZBM: A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with | Not stated | 3 | - | - |
| 2023-503660-17-00 Trial register | J1I-MC-GZBN:A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of | Not stated | 3 | - | - |
| NCT06982846 Trial register | A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia | completed | 1 | 2025-05-21 | - |
| NCT07357415 Trial register | A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | running, but no longer enrolling | 3 | 2026-01-22 | - |
| 2024-518470-13-00 Trial register | A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Not stated | 1 | - | - |
| NCT07232719 Trial register | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | running, but no longer enrolling | 3 | 2025-11-18 | - |
| NCT07467447 Trial register | Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight | currently recruiting participants | 2 | 2026-03-12 | - |
| NCT06354660 Trial register | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T | completed | 3 | 2024-04-09 | - |
| NCT06859268 Trial register | A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | running, but no longer enrolling | 3 | 2025-03-05 | - |
| NCT05931367 Trial register | A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | completed | 3 | 2023-07-05 | - |
| NCT05936151 Trial register | A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | completed | 2 | 2023-07-07 | - |
| 2024-518471-63-00 Trial register | A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia | Not stated | 1 | - | - |
| NCT06313528 Trial register | A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 | completed | 1 | 2024-03-11 | - |
| 2024-517431-43-00 Trial register | J1I-MC-GZQD: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who | Not stated | 3 | - | - |
| NCT06808802 Trial register | To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants | completed | 1 | 2025-02-05 | - |
| NCT05916560 Trial register | A Study of LY3437943 in Participants With Impaired and Normal Liver Function | completed | 1 | 2023-06-15 | - |
| NCT05959096 Trial register | A Study of LY3437943 in Healthy Participants With a High Body Mass Index | completed | 1 | 2023-07-17 | - |
| NCT06039826 Trial register | A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese | completed | 1 | 2023-09-11 | - |
| NCT06003465 Trial register | A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices | completed | 1 | 2023-08-16 | - |
| NCT05611957 Trial register | A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function | completed | 1 | 2022-11-03 | - |
| NCT04881760 Trial register | A Study of LY3437943 in Participants Who Have Obesity or Are Overweight | completed | 2 | 2021-05-10 | Posted |
| NCT05548231 Trial register | A Study of LY3437943 in Chinese Participants With Obesity Or Overweight | completed | 1 | 2022-09-16 | - |
| NCT04867785 Trial register | A Study of LY3437943 in Participants With Type 2 Diabetes | completed | 2 | 2021-04-30 | Posted |
| NCT05445232 Trial register | A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | completed | 1 | 2022-07-01 | - |
| NCT04823208 Trial register | A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) | completed | 1 | 2021-03-29 | - |
| NCT04143802 Trial register | A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | completed | 1 | 2019-10-29 | - |
| NCT03841630 Trial register | A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants | completed | 1 | 2019-02-13 | - |
Source: ClinicalTrials.gov and EU CTIS, read 2026-10-03. Not medical advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.